BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2878349)

  • 21. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ; Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H; Kuwert T; Lohmann T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical course and thyroid stimulating hormone (TSH) receptor antibodies during surgical treatment of Graves' disease.
    Mori Y; Matoba N; Miura S; Sakai N; Taira Y
    World J Surg; 1992; 16(4):647-52; discussion 652-3. PubMed ID: 1357830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Correlation between thyroid stimulating immunoglobulins and thyrotropin binding inhibitory immunoglobulins levels in patients with Graves' disease].
    Jonas M; Ambroziak U; Nauman J
    Endokrynol Pol; 2006; 57(1):23-30. PubMed ID: 16575759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in thyrotropin receptor antibody after subtotal thyroidectomy in Graves' disease: comparison with the degree of lymphocytic infiltration in the thyroid.
    Cho BY; Oh SK; Shong YK; Kim SE; Yoo HY; Lee HK; Koh CS; Min HK
    Autoimmunity; 1990; 8(2):143-7. PubMed ID: 1983330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients.
    Szabó J; Leövey A; Karányi Z; Várvölgyi C; Fórizs E; Herceg L
    Acta Med Hung; 1989; 46(1):23-30. PubMed ID: 2570399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similarity and dissimilarity between clinical and laboratory findings, especially anti-thyrotropin receptor antibody in ophthalmic Graves' disease without persistent hyperthyroidism and hyperthyroid Graves' disease.
    Kosugi S; Inoue D; Sugawa H; Enomoto T; Mori T; Imura H
    Endocrinol Jpn; 1990 Jun; 37(3):343-54. PubMed ID: 2253584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of TSH receptor-binding antibodies in Hashimoto's thyroiditis and Graves' disease.
    De Bruin TW; Braverman LE; Brown RS
    Am J Med Sci; 1990 May; 299(5):291-7. PubMed ID: 2337120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [TSH receptor antibody in hyperthyroid patients due to Graves' disease treated with antithyroid drugs].
    Yamada T
    Nihon Naibunpi Gakkai Zasshi; 1991 Dec; 67(12):1295-308. PubMed ID: 1723696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence against the importance in the disease process of antibodies to bovine thyroid-stimulating hormone found in some patients with Graves' disease.
    Noh J; Hamada N; Saito H; Oyanagi H; Ishikawa N; Momotani N; Ito K; Morii H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):107-13. PubMed ID: 2909548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of anti-TSH antibody in sera from patients with Graves' disease and other thyroid disorders.
    Akamizu T; Mori T; Imura H; Noh J; Hamada N; Ito K; Koizumi Y; Yamada T; Fujihira T; Eto S
    J Endocrinol Invest; 1989; 12(7):483-8. PubMed ID: 2571629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of thyrotropin binding inhibitor immunoglobulins in serum from untreated patients with hyperthyroid Graves' disease.
    Lu C; Kasagi K; Iida Y; Konishi J
    Immunol Lett; 1991 Jun; 28(3):233-6. PubMed ID: 1679417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyrotropin receptor non-mediated thyroid stimulating immunoglobulin in Graves' disease.
    Endo T; Haraguchi K; Ohmori M; Ikeda M; Ohta K; Onaya T
    Biochem Biophys Res Commun; 1991 Sep; 179(3):1543-7. PubMed ID: 1656957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
    Ochi Y; Kajita Y; Hamazu M; Nagata A
    Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera.
    Rotella CM; Zonefrati R; Toccafondi R; Valente WA; Kohn LD
    J Clin Endocrinol Metab; 1986 Feb; 62(2):357-67. PubMed ID: 2416769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.